Home » Newsletters » BioWorld Science

BioWorld Science

July 3, 2019

View Archived Issues

Neutrophils have antitumor effects, can improve clinical outcomes

Endogenous retrovirus has link to MS

MS-1768 acts as a specific dopamine D2 receptor partial agonist

Novel zebrafish model to study the role of STUB1 in ataxia

Dicerna to initiate clinical development of DCR-A1AT for A1AT deficiency-associated liver disease

FDA grants IND approval for phase I/II study of anti-Fc gamma RllB antibody

ANT-2681 demonstrates pH-dependent potency and in vitro antibacterial activity

First clinical efficacy and safety data for 225Ac-DOTATATE in GEP-NET

Strong immunoprotection with a Zika VLP vaccine in a murine model

PPNA-40: comparable activity to tigecycline in multidrug-resistant A. baumannii model

MediSynergics divulges compounds for parasitic diseases

Daiichi Sankyo discloses new EP300 and/or CBP inhibitors

Basilea Pharmaceutica patent describes mitochondrial inhibitors

Leo Pharma describes PDE4 and TNF-alpha release inhibitors

IDO1 inhibitors reported in Phenex Discovery Verwaltungs patent

Low-dose mercury causes heart failure in mice

Data reported from first-in-human ATB200-02 trial of ATB-200/AT-2221 combination in Pompe disease

Appili Therapeutics to advance antibiotic program

FDA places clinical hold on phase I trial of ACTR-087 for relapsed/refractory NHL

Phase III MINISTONE-2 study of Xofluza in children with influenza meets primary endpoint

Tracon advances phase I/II trial of androgen receptor antagonist TRC-253 in metastatic CRPC

European Commission approves Dovato for HIV-1 infection

Algernon's NP-120 reduces fibrosis in in vivo animal model study of IPF

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 2, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...